Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection.
10.1007/s11684-021-0834-9
- Author:
Weibao SONG
1
;
Hongjuan ZHANG
1
;
Yu ZHANG
1
;
Rui LI
1
;
Yanxing HAN
1
;
Yuan LIN
2
;
Jiandong JIANG
3
Author Information
1. State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
2. State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. linyuan@imm.ac.cn.
3. State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. jiang.jdong@163.com.
- Publication Type:Review
- Keywords:
ZIKV inhibitors;
Zika virus;
antivirals;
clinical drugs;
repurposing
- MeSH:
Adult;
Animals;
Drug Repositioning;
Humans;
Infant, Newborn;
Microcephaly;
Pharmaceutical Preparations;
Zika Virus;
Zika Virus Infection/prevention & control*
- From:
Frontiers of Medicine
2021;15(3):404-415
- CountryChina
- Language:English
-
Abstract:
Zika virus (ZIKV) is an emerging pathogen associated with neurological complications, such as Guillain-Barré syndrome in adults and microcephaly in fetuses and newborns. This mosquito-borne flavivirus causes important social and sanitary problems owing to its rapid dissemination. However, the development of antivirals against ZIKV is lagging. Although various strategies have been used to study anti-ZIKV agents, approved drugs or vaccines for the treatment (or prevention) of ZIKV infections are currently unavailable. Repurposing clinically approved drugs could be an effective approach to quickly respond to an emergency outbreak of ZIKV infections. The well-established safety profiles and optimal dosage of these clinically approved drugs could provide an economical, safe, and efficacious approach to address ZIKV infections. This review focuses on the recent research and development of agents against ZIKV infection by repurposing clinical drugs. Their characteristics, targets, and potential use in anti-ZIKV therapy are presented. This review provides an update and some successful strategies in the search for anti-ZIKV agents are given.
